Geraldine OʼSullivan Coyne1, Alice Chen, Shivaani Kummar. 1. aDivision of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland bDivision of Medical Oncology, Department of Medicine, Stanford University, Stanford, California, USA.
Abstract
PURPOSE OF REVIEW: The article presents the rationale, clinical development, and current status of poly (ADP ribose) polymerase inhibitors (PARPis) as anticancer agents. RECENT FINDINGS: The recent approval of olaparib in heavily pretreated patients with advanced ovarian cancer carrying a BRCA1/2 mutation represents a significant therapeutic advance for patients with this difficult to treat disease. Though olaparib is the first agent in this class to be approved, multiple PARPis are in various stages of clinical development, including in combination with other treatment modalities such as radiation, antiangiogenic agents, and cytotoxic chemotherapies. SUMMARY: Clinical benefit has been observed with PARPis in patients with advanced BRCA1/2 mutant ovarian and breast cancers. Various PARPis, either as single agents or in combination, are being evaluated in the neoadjuvant, adjuvant, and metastatic settings.
PURPOSE OF REVIEW: The article presents the rationale, clinical development, and current status of poly (ADP ribose) polymerase inhibitors (PARPis) as anticancer agents. RECENT FINDINGS: The recent approval of olaparib in heavily pretreated patients with advanced ovarian cancer carrying a BRCA1/2 mutation represents a significant therapeutic advance for patients with this difficult to treat disease. Though olaparib is the first agent in this class to be approved, multiple PARPis are in various stages of clinical development, including in combination with other treatment modalities such as radiation, antiangiogenic agents, and cytotoxic chemotherapies. SUMMARY: Clinical benefit has been observed with PARPis in patients with advanced BRCA1/2 mutant ovarian and breast cancers. Various PARPis, either as single agents or in combination, are being evaluated in the neoadjuvant, adjuvant, and metastatic settings.
Authors: Stan B Kaye; Jan Lubinski; Ursula Matulonis; Joo Ern Ang; Charlie Gourley; Beth Y Karlan; Amit Amnon; Katherine M Bell-McGuinn; Lee-May Chen; Michael Friedlander; Tamar Safra; Ignace Vergote; Mark Wickens; Elizabeth S Lowe; James Carmichael; Bella Kaufman Journal: J Clin Oncol Date: 2011-12-27 Impact factor: 44.544
Authors: Panagiotis A Konstantinopoulos; Dimitrios Spentzos; Beth Y Karlan; Toshiyasu Taniguchi; Elena Fountzilas; Nancy Francoeur; Douglas A Levine; Stephen A Cannistra Journal: J Clin Oncol Date: 2010-06-14 Impact factor: 44.544
Authors: Arun Rajan; Ronan J Kelly; Jane B Trepel; Yeong Sang Kim; Sylvia V Alarcon; Shivaani Kummar; Martin Gutierrez; Sonja Crandon; Wadih M Zein; Lokesh Jain; Baskar Mannargudi; William D Figg; Brett E Houk; Michael Shnaidman; Nicoletta Brega; Giuseppe Giaccone Journal: Clin Cancer Res Date: 2011-09-09 Impact factor: 12.531
Authors: Kim A Reiss; Joseph M Herman; Marianna Zahurak; Anthony Brade; Laura A Dawson; Angela Scardina; Caitlin Joffe; Emily Petito; Amy Hacker-Prietz; Robert J Kinders; Lihua Wang; Alice Chen; Sarah Temkin; Naomi Horiba; Lillian L Siu; Nilofer S Azad Journal: Clin Cancer Res Date: 2014-10-29 Impact factor: 12.531
Authors: Malcolm A Smith; C Patrick Reynolds; Min H Kang; E Anders Kolb; Richard Gorlick; Hernan Carol; Richard B Lock; Stephen T Keir; John M Maris; Catherine A Billups; Dmitry Lyalin; Raushan T Kurmasheva; Peter J Houghton Journal: Clin Cancer Res Date: 2014-12-10 Impact factor: 12.531
Authors: Ruth Plummer; Christopher Jones; Mark Middleton; Richard Wilson; Jeffrey Evans; Anna Olsen; Nicola Curtin; Alan Boddy; Peter McHugh; David Newell; Adrian Harris; Patrick Johnson; Heidi Steinfeldt; Raz Dewji; Diane Wang; Lesley Robson; Hilary Calvert Journal: Clin Cancer Res Date: 2008-12-01 Impact factor: 12.531
Authors: Nuala McCabe; Nicholas C Turner; Christopher J Lord; Katarzyna Kluzek; Aneta Bialkowska; Sally Swift; Sabrina Giavara; Mark J O'Connor; Andrew N Tutt; Małgorzata Z Zdzienicka; Graeme C M Smith; Alan Ashworth Journal: Cancer Res Date: 2006-08-15 Impact factor: 12.701
Authors: Junko Murai; Shar-yin N Huang; Benu Brata Das; Amelie Renaud; Yiping Zhang; James H Doroshow; Jiuping Ji; Shunichi Takeda; Yves Pommier Journal: Cancer Res Date: 2012-11-01 Impact factor: 13.312
Authors: Nathan A Berger; Valerie C Besson; A Hamid Boulares; Alexander Bürkle; Alberto Chiarugi; Robert S Clark; Nicola J Curtin; Salvatore Cuzzocrea; Ted M Dawson; Valina L Dawson; György Haskó; Lucas Liaudet; Flavio Moroni; Pál Pacher; Peter Radermacher; Andrew L Salzman; Solomon H Snyder; Francisco Garcia Soriano; Robert P Strosznajder; Balázs Sümegi; Raymond A Swanson; Csaba Szabo Journal: Br J Pharmacol Date: 2017-03-26 Impact factor: 8.739